References
- Ben-Shabat S, Fride E, Sheskin T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. 1998;353(1):23–31.
- Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nat Prod Rep. 1999;16(2):131–143.
- Russo EB. The case for the entourage effect and conventional breeding of clinical cannabis: no “strain,” no gain. Front Plant Sci. 2018;9:1969.
- McPartland JM, Russo EB. Cannabis and cannabis extracts. J Cannabis Ther. 2001;1(3–4):103–132.
- Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–1364.
- Ferber SG, Namdar D, Hen-Shoval D, et al. The “entourage effect”: terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. Curr Neuropharmacol. 2019;18(2):87-96.
- Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234–246.
- Gupta S. Medical marijuana and “the entourage effect [Internet]. CNN; [cited 2019 July 21]. Available from: https://www.cnn.com/2014/03/11/health/gupta-marijuana-entourage/index.html
- Simon M. THC! CBD! Terpenoids! Cannabis science is getting hairy. Wired [Internet]; 2018 Nov 6 [cited 2019 July 21]. Available from: https://www.wired.com/story/cannabis-science-entourage-effect/
- Cannabis’s entourage effect: why whole plant medicine matters [Internet]. Leafly; 2015 [cited 2019 July 17]. Available from: https://www.leafly.com/news/cannabis-101/cannabis-entourage-effect-why-thc-and-cbd-only-medicines-arent-g
- Entourage effect archives • high times [Internet]. High Times; [cited 2019 Aug 13]. Available from: https://hightimes.com/tag/entourage-effect/
- Sponsor HT. Product selection should start with the entourage effect [Internet]. High Times; 2019 [cited 2019 July 21]. Available from: https://hightimes.com/sponsored/product-selection-should-start-with-the-entourage-effect/
- D’Amico EJ, Rodriguez A, Tucker JS, et al. Planting the seed for marijuana use: changes in exposure to medical marijuana advertising and subsequent adolescent marijuana use, cognitions, and consequences over seven years. Drug Alcohol Depend. 2018;188:385–391.
- D’Amico EJ, Miles JNV, Tucker JS. Gateway to curiosity: medical marijuana ads and intention and use during middle school. Psychol Addict Behav. 2015;29(3):613–619.
- CBD Isolate vs. full spectrum oil [Internet]. Papa Barkley; 2019 [cited 2019 Aug 14]. Available from: https://papaandbarkley.com/cbd-isolate-vs-full-spectrum-oil
- FAQ [Internet]. Sana CBD; 2018 [cited 2019 Aug 14]. Available from: https://sana-cbd.com/faq/
- What is the entourage effect? [Internet]. Anavii Mark; [cited 2019 Aug 14]. Available from: https://www.anaviimarket.com/blogs/news/what-is-the-entourage-effect
- February 08 CG·, 2019. CBD isolate vs. full spectrum CBD [Internet]. Axis Labs CBD; [cited 2019 Oct 12]. Available from: https://axislabscbd.com/blogs/news/cbd-isolate-vs-full-spectrum-cbd
- Russo EB. Current therapeutic cannabis controversies and clinical trial design issues. Front Pharmacol. 2016;7:309.
- Boggs DL, Nguyen JD, Morgenson D, et al. Clinical and preclinical evidence for functional interactions of cannabidiol and δ9-tetrahydrocannabinol. Neuropsychopharmacol. 2018;43(1):142–154.
- Carlini EA. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon. 2004;44(4):461–467.
- McKallip RJ, Nagarkatti M, Nagarkatti PS. Δ-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol. 2005;174(6):3281–3289.
- Zhu LX, Sharma S, Stolina M, et al. Δ-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol. 2000;165(1):373–380.
- Crippa JA, Guimarães FS, Campos AC, et al. Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol. [Internet]. 2018 [cited 2019 Sept 10];9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161644/
- Huestis MA, Solimini R, Pichini S, et al. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol. [Internet]. 2019 [cited 2019 Aug 21];17:974–989. Available from: http://europepmc.org/abstract/med/31161980
- DailyMed - EPIDIOLEX- cannabidiol solution [Internet]. [cited 2019 Mar 23]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec
- Russo C, Ferk F, Mišík M, et al. Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells. Arch Toxicol. 2019;93(1):179–188.
- Jansen C, Shimoda LMN, Kawakami JK, et al. Myrcene and terpene regulation of TRPV1. Channels Austin Tex. 2019;13(1):344–366.
- Hazekamp A, Tejkalová K, Papadimitriou S. Cannabis: from cultivar to chemovar II—a metabolomics approach to cannabis classification. Cannabis Cannabinoid Res. 2016;1(1):202–215.
- Cesta MF, Hard GC, Boyce JT, et al. Complex histopathologic response in rat kidney to oral β-myrcene: an unusual dose-related nephrosis and low-dose alpha2u-globulin nephropathy. Toxicol Pathol. 2013;41(8):1068–1077.
- Gordon WP, Forte AJ, McMurtry RJ, et al. Hepatotoxicity and pulmonary toxicity of pennyroyal oil and its constituent terpenes in the mouse. Toxicol Appl Pharmacol. 1982;65(3):413–424.
- Monzote L, Stamberg W, Staniek K, et al. Toxic effects of carvacrol, caryophyllene oxide, and ascaridole from essential oil of Chenopodium ambrosioides on mitochondria. Toxicol Appl Pharmacol. 2009;240(3):337–347.
- Waldman N. Seizure caused by dermal application of over-the-counter eucalyptus oil head lice preparation. Clin Toxicol. 2011;49(8):750–751.
- Mathew T, Kamath V, Kumar RS, et al. Eucalyptus oil inhalation–induced seizure: a novel, underrecognized, preventable cause of acute symptomatic seizure. Epilepsia Open. 2017;2(3):350–354.
- Fasinu PS, Bouic PJ, Rosenkranz B. An overview of the evidence and mechanisms of herb-drug interactions. Front Pharmacol. 2012;3:69.
- Klein P, Tolbert D, Gidal BE. Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures. Epilepsy Behav. 2019;99:106459.
- Bergmann KR, Broekhuizen K, Groeneveld GJ. Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency. Br J Clin Pharmacol. [Internet]. [cited 2019 Dec 10]. DOI:https://doi.org/10.1111/bcp.14158
- Anderson LL, Absalom NL, Abelev SV, et al. Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019;60:2224–2234.
- Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86–95.
- Jiang R, Yamaori S, Okamoto Y, et al. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28(4):332–338.
- Al Saabi A, Allorge D, Sauvage F-L, et al. Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Drug Metab Dispos Biol Fate Chem. 2013;41(3):568–574.
- Varvel SA, Wiley JL, Yang R, et al. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacol (Berl). 2006;186(2):226–234.
- Britch SC, Wiley JL, Yu Z, et al. Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity. Drug Alcohol Depend. 2017;175:187–197.
- Klein C, Karanges E, Spiro A, et al. Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacol (Berl). 2011;218(2):443–457.
- Karschner EL, Darwin WD, Goodwin RS, et al. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydro-cannabinol and oromucosal cannabis extract administration. Clin Chem. 2011;57(1):66–75.
- Wachtel S, ElSohly M, Ross S, et al. Comparison of the subjective effects of Δ9-tetrahydrocannabinol and marijuana in humans. Psychopharmacol (Berl). 2002;161(4):331–339.
- Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2010;35(3):764–774.
- Solowij N, Broyd S, Greenwood L, et al. A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci. [Internet]. 2019 [cited 2019 Jan 28];269:17–35.
- Birnbaum AK, Karanam A, Marino SE, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019;60(8):1586–1592.
- Namdar D, Voet H, Ajjampura V, et al. Terpenoids and phytocannabinoids co-produced in cannabis sativa strains show specific interaction for cell cytotoxic activity (supplementary material). Molecules. 2019;24(17):3031.
- Alén R. Chapter 3A - pulp mills and wood-based biorefineries. In: Pandey A, Höfer R, Taherzadeh M, et al., editors. Industrial Biorefineries and White Biotechnology [Internet]. Amsterdam: Elsevier; [cited 2019 Sept 29]. p. 91–1262015 Available from: http://www.sciencedirect.com/science/article/pii/B9780444634535000033
- Baram L, Peled E, Berman P, et al. The heterogeneity and complexity of cannabis extracts as antitumor agents. Oncotarget. 2019;10(41):4091–4106.
- Mannila J, Järvinen T, Järvinen K, et al. Precipitation complexation method produces cannabidiol/beta-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol. J Pharm Sci. 2007;96(2):312–319.
- Hazekamp A, Verpoorte R. Structure elucidation of the tetrahydrocannabinol complex with randomly methylated β-cyclodextrin. Eur J Pharm Sci. 2006;29(5):340–347.
- Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharm Stat. 2011;10(2):128–134.
- Zuardi AW, Hallak JEC, Crippa JAS. Interaction between cannabidiol (CBD) and ∆(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacol (Berl). 2012;219(1):247–249.
- Finn DP, Beckett SRG, Roe CH, et al. Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci. 2004;19(3):678–686.
- Harris HM, Rousseau MA, Wanas AS, et al. Role of cannabinoids and terpenes in cannabis-mediated analgesia in rats. Cannabis Cannabinoid Res. 2019;4(3):177–182.
- Hayakawa K, Mishima K, Hazekawa M, et al. Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism. Brain Res. 2008;1188:157–164.
- Murkar A, Kent P, Cayer C, et al. Cannabidiol and the remainder of the plant extract modulate the effects of δ9-tetrahydrocannabinol on fear memory reconsolidation. Front Behav Neurosci. 2019;13:174.
- MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–19.
- Chen A. Some of the parts: is marijuana’s “entourage effect” scientifically valid? Sci Am [Internet]. [cited 2019 Sept 10]. Available from: https://www.scientificamerican.com/article/some-of-the-parts-is-marijuana-rsquo-s-ldquo-entourage-effect-rdquo-scientifically-valid/
- Bhattacharyya S, Atakan Z, Martin-Santos R, et al. Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2015;25(1):26–37.
- Sellers EM, Schoedel K, Bartlett C, et al. A multiple-dose, randomized, double-blind, placebo-controlled, parallel-group QT/QTc study to evaluate the electrophysiologic effects of THC/CBD spray. Clin Pharmacol Drug Dev. 2013;2(3):285–294.
- Desrosiers NA, Ramaekers JG, Chauchard E, et al. Smoked cannabis’ psychomotor and neurocognitive effects in occasional and frequent smokers. J Anal Toxicol. 2015;39(4):251–261.
- DailyMed - MARINOL- dronabinol capsule [Internet]. [cited 2019 Mar 23]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bbac0b1-ddc2-400b-8e0d-1e1d484720ca
- Favrat B, Ménétrey A, Augsburger M, et al. Two cases of “cannabis acute psychosis” following the administration of oral cannabis. BMC Psychiatry. 2005;5:17.
- Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol Oxf Engl. 2013;27(1):19–27.
- Freeman D, Pugh K, Green C, et al. A measure of state persecutory ideation for experimental studies. J Nerv Ment Dis. 2007;195(9):781.
- Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and thc extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167–179.
- Killestein J, Hoogervorst ELJ, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58(9):1404–1407.
- Cogan PS. On healthcare by popular appeal: critical assessment of benefit and risk in cannabidiol based dietary supplements. Expert Rev Clin Pharmacol. 2019;12(6):501–511.
- Pamplona FA, da Silva LR, Coan AC. Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 2018;9:759.
- Cross JH, Cock H. A perspective on cannabinoids for treating epilepsy: do they really change the landscape?. Neuropharmacology. 2019;107861.
- Schoedel KA, Chen N, Hilliard A, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol. 2011;26(3):224–236.
- Karschner EL, Darwin WD, McMahon RP, et al. Subjective and physiological effects after controlled sativex and oral THC administration. Clin Pharmacol Ther. 2011;89(3):400–407.
- Hart CL, Ward AS, Haney M, et al. Comparison of smoked marijuana and oral Δ9-tetrahydrocannabinol in humans. Psychopharmacol (Berl). 2002;164(4):407–415.
- Haney M, Malcolm RJ, Babalonis S, et al. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology. 2016;41(8):1974–1982.
- Santiago M, Sachdev S, Arnold JC, et al. Absence of entourage: terpenoids commonly found in Cannabis sativa do not modulate the functional activity of Δ9-THC at human CB1and CB2 receptors. bioRxiv. 2019;569079.
- Blasco-Benito S, Seijo-Vila M, Caro-Villalobos M, et al. Appraising the “entourage effect”: antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochem Pharmacol. 2018;157:285–293.
- Kuszak AJ, Hopp DC, Williamson JS, et al. Approaches by the US national institutes of health to support rigorous scientific research on dietary supplements and natural products. Drug Test Anal. 2016;8(3–4):413–417.
- Sink R, Gobec S, Pečar S, et al. False positives in the early stages of drug discovery. Curr Med Chem. 2010;17(34):4231–4255.
- Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114–118.
- DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
- Harrison RK. Phase II and phase III failures: 2013–2015. Nat Rev Drug Discov. 2016;15(12):817–818.
- Commissioner O of the. A brief history of the center for drug evaluation and research. FDA [Internet]; 2019 [cited 2019 July 24]. Available from: http://www.fda.gov/about-fda/virtual-exhibits-fda-history/brief-history-center-drug-evaluation-and-research
- Navari RM, Aapro M. antiemetic prophylaxis for chemothe-rapy-induced nausea and vomiting. N Engl J Med. 2016;374(14):1356–1367.
- Piomelli D, Russo EB. The cannabis sativa versus cannabis indica debate: an interview with ethan russo, MD. Cannabis Cannabinoid Res. 2016;1(1):44–46.
- Can CBD undo the anxious side effects of THC? [Internet]. Leafly; 2016 [cited 2019 Dec 14]. Available from: https://www.leafly.com/news/cannabis-101/can-cbd-undo-the-anxious-side-effects-of-thc
- Bergamaschi MM, Queiroz RHC, Zuardi AW, et al. Safety and side effects of cannabidiol, a cannabis sativa constituent. Curr Drug Saf. 2011;6(4):237–249.
- What is couch lock and how to beat it - Cannaconnection.com [Internet]. [cited 2019 Sept 28]. Available from: https://www.cannabis.info/en/blog/18034-what-is-couch-lock-how-beat-it
- Crippa JA, Zuardi AW, Martín‐Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol Clin Exp. 2009;24(7):515–523.
- Dannon PN, Lowengrub K, Amiaz R, et al. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Hum Psychopharmacol Clin Exp. 2004;19(2):97–101.
- Rohleder C, Müller JK, Lange B, et al. Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence Front Pharmacol [Internet]. 2016 [cited 2019 July 22];7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099166/
- Johns A. Psychiatric effects of cannabis. Br J Psychiatry. 2001;178(2):116–122.
- Crippa JAS, Crippa ACS, Hallak JEC, et al. Δ9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Front Pharmacol. [Internet]. 7 2016 [cited 2019 Oct 15]DOI:https://doi.org/10.3389/fphar.2016.00359/full
- Src=’https://Secure.gravatar.com/Avatar/2f28bfe94d2b407b1b27b57c63866fa6?s=250 <img Alt=“, #038;d=https%3A%2F%2Fgreenflowerbotanicals.com%2Fwp-content%2Fthemes%2F2018greenflowerbotanicals%2Fimg%2Fgravatar.jpg, Srcset=’https://Secure.gravatar.com/Avatar/2f28bfe94d2b407b1b27b57c63866fa6?s=500 #038;r=g’, et al. Strain terpenes – nature’s medicinal secret [Internet]. [cited 2020 Jan 15]. Available from: https://greenflowerbotanicals.com/terpenes-natures-medicinal-powerhouses/
- Humphreys K, Hall WD. Reducing the risks of distortion in cannabis research. Addict Abingdon Engl. 2019.
- Dickson B, Mansfield C, Guiahi M, et al. Recommendations from cannabis dispensaries about first-trimester cannabis use. Obstet Gynecol. 2018;131(6):1031.
- Pellechia T. Legal cannabis industry poised for big growth, in North America and around the world [Internet]. Forbes; [cited 2019 Oct 16]. Available from: https://www.forbes.com/sites/thomaspellechia/2018/03/01/double-digit-billions-puts-north-america-in-the-worldwide-cannabis-market-lead/